Instil Bio Receives FDA Approval to Initiate Expanded Phase 2 Advanced Melanoma Study
Source: Streetwise Reports  (9/15/21)
Shares of Instil Bio Inc. traded 16% higher after the company reported it received IND clearance from the U.S. FDA to initiate a Phase 2 clinical trial in advanced melanoma patients. More >

Biopharma Co. Posts Positive Objective Response & Disease Control Rates in Ovarian Cancer Studies
Source: Streetwise Reports  (9/14/21)
H.C. Wainwright & Co. advised in a research report that updated data from Mersana Therapeutics Inc.'s expansion study supports its UPLIFT Study and will provide the basis for a new Phase 3 study in 2022. H.C. Wainwright rates Mersana a "Buy" with a target price of $28.00/share. More >

aTyr Pharma's Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis Trial
Source: Streetwise Reports  (9/13/21)
Shares of aTyr Pharma Inc. traded 48% higher after the firm reported its ATYR1923 produced positive results in a Phase 1b/2a clinical study by demonstrating consistent favorable dose responses in pulmonary sarcoidosis patients. More >

Sanofi Makes US$1.9 Billion Offer to Buy Kadmon Holdings to Solidify Its Transplant Business
Source: Streetwise Reports  (9/8/21)
Shares of Kadmon Holdings Inc. traded 70% higher after the firm reported it agreed to be acquired by Sanofi SA for $9.50 per share in cash. Sanofi aims to strengthen its transplant business with the addition of Kadmon's Rezurockâ„¢ (belumosudil), an FDA-approved, first-in-class treatment for patients 12 years and older with chronic graft-versus-host disease. More >

Medical Device Company's Improved Fundamentals Offer Multiple Expansion Potential
Source: Streetwise Reports  (9/7/21)
ROTH Capital Partners LLC commented in a research report that it is maintaining its "Buy" rating and raising its FY/22 revenue estimates for Dynatronics Corp. to $41 million after the firm pre-announced Q4/21 revenue figures that exceeded prior estimates. More >

Adaptimmune Partners With Genentech to Develop & Market Cancer-Targeted Allogeneic T-Cell Therapies
Source: Streetwise Reports  (9/7/21)
Adaptimmune Therapeutics Plc. shares traded 33% higher after the firm reported it formed a strategic partnership with Genentech to develop several "off-the-shelf" and advanced personalized cancer-targeting allogeneic T-cell therapies. More >

Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD Tech
Source: Streetwise Reports  (9/4/21)
Shares of Impel NeuroPharma Inc. traded to a new 52-week high after the company reported that the U.S. Food and Drug Administration has approved TRUDHESAâ„¢ (dihydroergotamine mesylate), a patient friendly nasal spray that delivers rapid relief and treatment for acute migraine. More >

Reliq Health Technologies Rides Telehealth Reimbursement Wave
Source: Streetwise Reports  (9/2/21)
Global telemedicine company will turn a profit in the current quarter and experience rapid growth after new contracts to provide chronic care management and medicare and medicaid reimbursements expand. More >

Biopharma's Antibody Approved as Hodgkin's Lymphoma Treatment in China
Source: Streetwise Reports  (8/31/21)
"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report. More >

AC Immune Shares Rise 16% After Phase 2 Alzheimer's Trial Data Shows Significant Reductions in Cognitive Decline
Source: Streetwise Reports  (8/31/21)
AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease. More >

Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21
Source: Streetwise Reports  (8/30/21)
The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report. More >

Third Implantation of Device Firm's Total Artificial Heart That 'Could Save Many Patients Who May Die'
Source: Streetwise Reports  (8/30/21)
An H.C. Wainwright & Co. report noted that Carmat's Aeson implant "could save many patients who may die, due to [a] shortage of donor hearts, while waiting for a heart transplant." More >

Poseida Shares Point Higher After FDA Clears NDA for Relapsed/Refractory Multiple Myeloma Treatment Candidate
Source: Streetwise Reports  (8/30/21)
Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma. More >

Bolt Bio Partners With Innovent Biologics to Create Three New Cancer Treatments
Source: Streetwise Reports  (8/28/21)
Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbodyâ„¢ ISAC programs. More >

Dermatological Device Company to Acquire Laser System Firm
Source: Streetwise Reports  (8/24/21)
An H.C. Wainwright report noted that "this deal is an opportunity for STRATA Skin Sciences to substantially increase its long-term, recurring revenue base." More >

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon
Source: Streetwise Reports  (8/24/21)
A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile." More >

Biopharma's Amino Acid Compound Shows Anti-Inflammatory Effect
Source: Streetwise Reports  (8/23/21)
Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report. More >

Trillium Receives US$2.26B Buyout Bid, Shares Trade 190% Higher
Source: Streetwise Reports  (8/23/21)
Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash. More >

Specialty Pharma's Q2/21 Results 'Fundamentally Ahead of Expectations'
Source: Streetwise Reports  (8/23/21)
A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction. More >

Flora Shares Sprout Higher on H1 Financial Results and Positive FY Sales Outlook
Source: Streetwise Reports  (8/20/21)
Shares of natural cannabis firm Flora Growth Corp. rose 43% after the company reported H1/21 financial results and indicated it expects H2/21 revenues will be in the range of US$9-11 million. More >

Inovalon Receives $7.3 Billion Buyout Offer From Nordic Capital Led Equity Consortium
Source: Streetwise Reports  (8/19/21)
Inovalon Holdings Inc. shares traded 8% higher after the cloud healthcare technology platform firm reported it entered into an agreement to be acquired by an equity consortium led by Nordic Capital and Insight Partners for $41.00 per share in cash. More >

Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials
Source: Streetwise Reports  (8/18/21)
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. More >

Global Specialty Pharma Co. Strongly Beats on Consensus Q2 Revenue and Earnings Estimates
Source: Streetwise Reports  (8/18/21)
Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months. More >

Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales
Source: Streetwise Reports  (8/18/21)
Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential. More >

Diagnostics Firm Readies for Pivotal FDA Study of Device That Detects Bacterial Lung Infections
Source: Streetwise Reports  (8/18/21)
Promising early results and a new line of equity support Avisa Diagnostic’s drive for IDE approval of its rapid-response breath test for pneumonia, TB, CF, and other lung ailments. More >